Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From MAP Pharmaceuticals

Allergan Moves Into Busy CGRP Class By Buying Merck’s Oral Drugs

Allergan agreed to pay $250 million up front for global rights two investigational oral CGRP antagonists in early clinical development for acute treatment and prevention of migraine. Several rivals are racing to develop injectable CGRP antibodies.

BioPharmaceutical Clinical Trials

Sanofi pays $45m for early look-in on genetic heart disease program

Sanofi has paid $45m via an upfront licensing fee and equity investment in young South San Francisco-based biotech MyoKardia, which is developing targeted therapies for genetic heart disease. The collaboration is an outgrowth of Sanofi's Sunrise initiative, a partnership model focused on early stage opportunities.

Cardiovascular Companies

Allergan Manufacturing Headaches Continue For Semprana

Inhalable acute migraine drug previously known as Levadex receives third “complete response” letter from FDA.

BioPharmaceutical Manufacturing

Rejection, approval & 2 moves to PhIII change Allergan conversation

For the third time, the FDA has rejected Allergan's experimental inhaled migraine drug dihydroergotamine, which has now changed its moniker from Levadex to Semprana.

Metabolic Disorders Orthopedics
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
      • Site Specific